Profit without a product
How does a clinical-stage biotherapeutics group with only a few million dollars of Revenue report a half-year profit of more than US$60 million? PureTech Health's interim report for the six months to 30 June 2026 answers that question, and the answer says more about the value of its stakes in other companies than about its own operating economics.
The hub-and-spoke model
PureTech (LSE:PRTC) is listed on the London Stock Exchange's Main Market. It describes itself as "a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value". In practice, it develops therapeutic candidates internally and then places them in separately funded companies, keeping stakes and, in some cases, royalties.
Its main interests include a 35.4% stake in Celea Therapeutics, which is running a Phase 3 trial of deupirfenidone (LYT-100) in idiopathic pulmonary fibrosis; full ownership of Gallop Oncology, developing the anti-galectin-9 antibody LYT-200 for a form of blood cancer; and a 31.2% stake in Seaport Therapeutics, which listed on Nasdaq in May 2026. PureTech also receives royalties from Bristol Myers Squibb on sales of the schizophrenia drug Cobenfy. Celea completed a US$180m financing after the period end, according to the report.
What the half-year report showed
On 22 September 2026, PureTech published its half-year report. The company reported Net Income attributable to owners of US$67.2m, against a loss of US$44.6m a year earlier, while its operating loss was US$52.3m.
The report explained that, following Seaport's initial public offering on 1 May 2026, the Investment is now measured at its quoted market price. This produced a Fair Value gain of US$120.4m. A further US$38.3m was recognised when Seaport pre-IPO shares moved from associate accounting to fair value. The report put the Seaport stake at around US$360m as of 18 September 2026.
The day before, on 21 September, PureTech announced that Gallop had received FDA Fast Track Designation for LYT-200 after a positive meeting with the regulator. The designation is intended to speed development and review of drugs for serious conditions, though it does not ensure approval.
Operating performance and cash
Beneath the gains, the company is still spending more than it earns. Revenue, all Royalty income from Cobenfy, rose 92% to US$3.6m from US$1.9m. Operating expenses increased to US$55.9m from US$49.8m, with R&D spending up to US$33.9m from US$24.9m, reflecting the start of Celea's Phase 3 SURPASS-IPF trial in July.
PureTech-level cash, cash equivalents and short-term investments fell to US$220.0m from US$277.0m at the end of 2025. The company said this provides an operational runway at least through the end of 2028 without counting on future monetisation events. Chief executive Robert Lyne indicated that Capital returns are expected to play "a more meaningful role" in allocating future proceeds, though no buyback programme was set out in the report.
Risks and milestones
The reported profit depends heavily on Seaport's share price, so a weaker Nasdaq valuation could reverse part of the gain in later periods. Cash also continues to decline as trials progress further. Key dates are distant: Celea's topline Phase 3 results are expected in the second half of 2029, Seaport's Phase 2b GlyphAllo data in depression are guided for the first half of 2027, and Gallop is seeking external capital for its Phase 2 STRIDE-MDS study in the first half of 2027. Clinical, regulatory and funding risks apply to each programme.
Conclusion
PureTech moved into profit for the half year mainly because Seaport's listing allowed its stake to be revalued at market price, not because its own operations turned profitable. The underlying picture is one of rising R&D spending, growing but small royalty income and a cash balance management says lasts into 2028, with clinical readouts still some way off.






Please wait processing your request...